Trinity Biotech (TRIB) to Release Quarterly Earnings on Thursday

Trinity Biotech (NASDAQ:TRIB) is projected to issue its Q4 2024 quarterly earnings data before the market opens on Thursday, May 22nd. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $16.50 million for the quarter.

Trinity Biotech Trading Down 3.2%

TRIB stock opened at $0.82 on Tuesday. The stock’s fifty day simple moving average is $0.67 and its two-hundred day simple moving average is $0.86. Trinity Biotech has a 1-year low of $0.48 and a 1-year high of $3.55. The stock has a market cap of $14.80 million, a P/E ratio of -0.36 and a beta of 0.86.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Trinity Biotech in a research report on Saturday. They issued a “sell” rating on the stock.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.